Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.

Matteo BramuzzoSerena ArrigoClaudio RomanoMaria Chiara FilardiPaolo LionettiAnna AgrustiValeria DipasqualeMonica PaciGiovanna ZuinMarina AloiCaterina StrisciuglioErasmo MieleMaria PastoreStefano MartelossiPatrizia Alvisinull null

Published in: United European gastroenterology journal (2019)

Compared with older children, VEO-IBD patients have higher rates of infliximab failures, lower remission rates at one year, and more often experience adverse events during induction.

Keyphrases

early onset
ulcerative colitis
late onset
end stage renal disease
ejection fraction
young adults
prognostic factors
quality improvement
systemic lupus erythematosus